Gilead Sciences’ Chief Financial Officer Robin Washington to Step Down in Early 2020
01 May 2019 - 6:27AM
Business Wire
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Robin
Washington, Executive Vice President (EVP) and Chief Financial
Officer (CFO), plans to retire from her role, effective March 1,
2020.
Ms. Washington will continue as EVP and CFO while the company
works to identify a successor. Should a CFO be named before March
1, 2020, Ms. Washington has agreed to remain in an advisory
capacity through the completion of the company’s reporting of 2019
financial results to ensure a smooth transition.
“During my short time here, I have been impressed with the
strategic expertise that Robin brings to her role and the
dedication she has for our mission and the patients we serve. It is
equally clear that she has built a strong team across the
organizations she leads,” said Daniel O’Day, Chairman and Chief
Executive Officer. “Robin is an outstanding leader and it comes as
no surprise that she has agreed to remain with Gilead through the
completion of the company’s reporting of 2019 financial
results.”
Ms. Washington joined Gilead in 2008 and is currently
responsible for leading the company’s finance, investor relations,
facilities and operations, and information technology
organizations. Ms. Washington also is a Board Director for
Honeywell Inc., Salesforce.com and, this afternoon, was named to
Alphabet Inc.’s Board of Directors.
“It has been my great honor to serve as Gilead’s CFO for more
than 10 years, and to work alongside the talented team we have in
place across our CFO organization and Gilead at large. Together,
we’ve played a role in the important work this company does to
deliver ground-breaking treatment advances to people all over the
world,” said Ms. Washington. “I am committed to working with Dan,
the rest of the leadership team and my colleagues over the coming
months to ensure that this transition process is a seamless
one.”
As previously announced, Gilead is reporting first quarter 2019
earnings results on May 2, 2019.
About Gilead Sciences
Gilead Sciences, Inc. is a research-based biopharmaceutical
company that discovers, develops and commercializes innovative
medicines in areas of unmet medical need. The company strives to
transform and simplify care for people with life-threatening
illnesses around the world. Gilead has operations in more than 35
countries worldwide, with headquarters in Foster City,
California.
Forward-Looking
Statement
This press release includes forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
that are subject to risks, uncertainties and other factors. These
risks, including the risk that Ms. Washington may leave prior to
the currently anticipated timeline, and other factors could cause
actual events to differ materially from those referred to in the
forward-looking statements. The reader is cautioned not to rely on
these forward-looking statements. These and other risks are
described in detail in Gilead’s Annual Report on Form 10-K for the
year ended December 31, 2018, as filed with the U.S. Securities and
Exchange Commission. All forward-looking statements are based on
information currently available to Gilead, and Gilead assumes no
obligation to update any such forward-looking statements.
For more information about Gilead please visit
the company's website at www.gilead.com, follow Gilead on Twitter
(@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5
or 1-650-574-3000.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190430006202/en/
Sung Lee, Investors(650) 524-7792
Amy Flood, Media(650) 522-5643
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Apr 2024 to May 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From May 2023 to May 2024